AKTS
Aktis Oncology, Inc.
$21.93
+12.69%
$1.2B
No data for this timeframe.
Vol
Market Cap$1.2B
Cap SizeSmall Cap
Analyst ConsensusStrong Buy (92%)
Inst. Holders41 funds
Inst. Value$237.9M
Inst. Activity6 buys / 0 sells
SEC Reports1
Press Releases3
Recent Activity
May 11, 2026
SEC
Aktis Oncology reported Q1 2026 financial results, highlighting a net loss of $18.3 million (vs. $15.0 million a year ag
8-K — Impact 4/10
Apr 15, 2026
Insider
Gormley Glenn was granted 37,866 shares
Director
Inst.
WELLINGTON MANAGEMENT GROUP LLP — NEW
2,317,044 shares ($41.5M)
Inst.
BlackRock, Inc. — NEW
2,112,127 shares ($37.8M)
May 27, 2026
other
Aktis Oncology to Present at the Jefferies Global Healthcare Conference
<p>BOSTON, May 27, 2026 (GLOBE NEWSWIRE) -- Aktis Oncology, Inc. (NASDAQ:AKTS) (the “Company”), a
May 21, 2026
Press
Aktis reported first-in-human clinical imaging and dosimetry data for AKY-2519, a B7-H3-targeted miniprotein radioconjug
Impact 7/10
Apr 21, 2026
Press
Aktis Oncology announced upcoming ASCO poster presentations showcasing clinical imaging and dosimetry data for AKY-2519,
Impact 4/10
Price Targets
$32.65
+48.9% upside
Strong Buy
Current $21.93
Low $30.00
Median $33.00
High $35.00
5 analysts
$30.00
$35.00
Analyst Ratings
5Strong Buy
6Buy
1Hold
0Sell
0Strong Sell
Recent Analyst Actions
| Date | Firm | Action | Rating |
|---|---|---|---|
| Jun 2, 2026 | HC Wainwright & Co. | MAINTAIN | Buy → Buy |
| Apr 29, 2026 | William Blair | INITIATE | Outperform |
| Mar 31, 2026 | HC Wainwright & Co. | MAINTAIN | Buy → Buy |
| Mar 9, 2026 | HC Wainwright & Co. | INITIATE | Buy |
| Feb 3, 2026 | Leerink Partners | INITIATE | Outperform |
Earnings Estimates
| Period | EPS Est. | Range | Growth | # |
|---|---|---|---|---|
| Current Q | $-0.45 ▼ -28.6% | $-0.53 — $-0.36 | 4 | |
| Next Q | $-0.48 ▼ -20.6% | $-0.55 — $-0.41 | 4 | |
| Current FY | $-1.59 ▼ -18.3% | $-2.08 — $-1.12 | 98% YoY | 5 |
| Next FY | $-1.99 ▼ -10.3% | $-3.07 — $-1.41 | -25% YoY | 5 |
Latest Reports
BULLISH
Press
7/10
Aktis reported first-in-human clinical imaging and dosimetry data for AKY-2519, a B7-H3-targeted miniprotein radioconjug
May 21, 2026
NEUTRAL
8-K
4/10
Aktis Oncology reported Q1 2026 financial results, highlighting a net loss of $18.3 million (vs. $15.0 million a year ag
May 11, 2026
Top Institutional Holders
| Fund | Value | Move |
|---|---|---|
| WELLINGTON MANAGEMENT GROUP LLP | $41.5M | NEW |
| BlackRock, Inc. | $37.8M | NEW |
| RTW INVESTMENTS, LP | $28.5M | NEW |
| RA CAPITAL MANAGEMENT, L.P. | $26.9M | NEW |
| JANUS HENDERSON GROUP PLC | $26.0M | NEW |
Recent Insider Trades
| Date | Insider | Type | Value |
|---|---|---|---|
| Apr 15, 2026 | Gormley Glenn | A | $0.00 |
41 institutional holders with $237.9M total value (14,860,301 shares) as of 2026-Q1. Top holders: WELLINGTON, BlackRock,, RTW. Net buying activity: 6 institutions added/increased vs 0 reduced.
Top Institutional Holders — 2026-Q1
| # | Fund | Shares | Value | % of Tracked | Last Move |
|---|---|---|---|---|---|
| 1 | WELLINGTON MANAGEMENT GROUP LLP | 2,317,044 | $41.5M | 17.4% | NEW |
| 2 | BlackRock, Inc. | 2,112,127 | $37.8M | 15.9% | NEW |
| 3 | RTW INVESTMENTS, LP | 1,592,043 | $28.5M | 12.0% | NEW |
| 4 | RA CAPITAL MANAGEMENT, L.P. | 1,503,084 | $26.9M | 11.3% | NEW |
| 5 | JANUS HENDERSON GROUP PLC | 1,454,267 | $26.0M | 10.9% | NEW |
| 6 | BAKER BROS. ADVISORS LP | 996,351 | $17.8M | 7.5% | NEW |
| 7 | VANGUARD CAPITAL MANAGEMENT LLC | 833,913 | $14.9M | 6.3% | — |
| 8 | STATE STREET CORP | 428,253 | $7.7M | 3.2% | — |
| 9 | FMR LLC | 386,379 | $6.9M | 2.9% | — |
| 10 | Alyeska Investment Group, L.P. | 290,000 | $5.2M | 2.2% | — |
| 11 | CHARLES SCHWAB INVESTMENT MANAGEMENT INC | 162,017 | $2.9M | 1.2% | — |
| 12 | DRIEHAUS CAPITAL MANAGEMENT LLC | 150,000 | $2.7M | 1.1% | — |
| 13 | VANGUARD FIDUCIARY TRUST CO | 127,395 | $2.3M | 1.0% | — |
| 14 | VANGUARD PORTFOLIO MANAGEMENT LLC | 120,322 | $2.2M | 0.9% | — |
| 15 | AMERIPRISE FINANCIAL INC | 102,925 | $1.8M | 0.8% | — |
| 16 | TD ASSET MANAGEMENT INC | 100,962 | $1.8M | 0.8% | — |
| 17 | SOROS FUND MANAGEMENT LLC | 100,000 | $1.8M | 0.8% | — |
| 18 | Woodline Partners LP | 100,000 | $1.8M | 0.8% | — |
| 19 | CITADEL ADVISORS LLC | 75,000 | $1.3M | 0.6% | — |
| 20 | BANK OF AMERICA CORP /DE/ | 69,926 | $1.3M | 0.5% | — |
Recent Position Changes
| Fund | Action | Prev Shares | Curr Shares | Change % | Value | Quarter |
|---|---|---|---|---|---|---|
| WELLINGTON MANAGEMENT GROUP LLP | NEW | — | 2,317,044 | — | $41.5M | 2026-Q1 |
| BlackRock, Inc. | NEW | — | 2,112,127 | — | $37.8M | 2026-Q1 |
| RTW INVESTMENTS, LP | NEW | — | 1,592,043 | — | $28.5M | 2026-Q1 |
| RA CAPITAL MANAGEMENT, L.P. | NEW | — | 1,503,084 | — | $26.9M | 2026-Q1 |
| JANUS HENDERSON GROUP PLC | NEW | — | 1,454,267 | — | $26.0M | 2026-Q1 |
| BAKER BROS. ADVISORS LP | NEW | — | 996,351 | — | $17.8M | 2026-Q1 |
1 unique insiders with 1 transactions. Net insider value: $0.00 ($0.00 bought, $0.00 sold).
Insider Transactions
| Date | Insider | Title | Type | Shares | Price | Value |
|---|---|---|---|---|---|---|
| Apr 15, 2026 | Gormley Glenn | Director | AWARD | 37,866 | — | — |
1 SEC filing reports analyzed. Sentiment: 0 bullish, 0 bearish, 0 mixed, 1 neutral. Avg impact: 4.0/10.
BULLISH
7/10
Aktis reported first-in-human clinical imaging and dosimetry data for AKY-2519, a B7-H3-targeted min
May 21, 2026
NEUTRAL
4/10
Aktis Oncology announced upcoming ASCO poster presentations showcasing clinical imaging and dosimetr
Apr 21, 2026
BULLISH
7/10
Aktis Oncology announced FDA clearance of IND applications for its AKY-2519 program, enabling a Phas
Mar 30, 2026
Current analyst consensus: Strong Buy (92% buy). Based on 12 analysts: 5 strong buy, 6 buy, 1 hold, 0 sell, 0 strong sell.
Analyst Price Targets
$32.65 mean target
+48.9% upside
Strong Buy (1.17)
$30.00 Low
$35.00 High
| Metric | Value |
|---|---|
| Current Price | $21.93 |
| Target Low | $30.00 |
| Target Mean | $32.65 |
| Target Median | $33.00 |
| Target High | $35.00 |
| # Analysts | 5 |
| Recommendation | Strong Buy (1.17) |
Earnings Estimates & Revisions
| Period | EPS Avg | EPS Low | EPS High | EPS Growth | 30d Rev. | Up/Down | Rev. Avg | Rev. Growth | Analysts |
|---|---|---|---|---|---|---|---|---|---|
| Current Q 2026-06-30 |
$-0.45 | $-0.53 | $-0.36 | — | -28.6% | 0↑ 2↓ | $0.0B | — | 4 |
| Next Q 2026-09-30 |
$-0.48 | $-0.55 | $-0.41 | — | -20.6% | 0↑ 2↓ | $0.0B | — | 4 |
| Current FY 2026-12-31 |
$-1.59 | $-2.08 | $-1.12 | 98.0% | -18.3% | 0↑ 2↓ | $0.0B | 85.4% | 5 |
| Next FY 2027-12-31 |
$-1.99 | $-3.07 | $-1.41 | -24.9% | -10.3% | 0↑ 2↓ | $0.0B | 15.1% | 5 |
Current Quarter EPS Revision History
| Timepoint | EPS Estimate | Change |
|---|---|---|
| Current | $-0.450 | |
| 7d ago | $-0.480 | +0.030 |
| 30d ago | $-0.350 | -0.100 |
| 60d ago | $-0.350 | -0.100 |
| 90d ago | $-0.365 | -0.085 |
4 analyst firms have rated this stock: 0 upgrades, 0 downgrades, 4 initiations.
Individual Analyst Actions
| Date | Analyst Firm | Action | Previous Rating | New Rating |
|---|---|---|---|---|
| Jun 2, 2026 | HC Wainwright & Co. | MAINTAIN | Buy | Buy |
| Apr 29, 2026 | William Blair | INITIATE | — | Outperform |
| Mar 31, 2026 | HC Wainwright & Co. | MAINTAIN | Buy | Buy |
| Mar 9, 2026 | HC Wainwright & Co. | INITIATE | — | Buy |
| Feb 3, 2026 | Leerink Partners | INITIATE | — | Outperform |
| Feb 3, 2026 | JP Morgan | INITIATE | — | Overweight |
Monthly Consensus History
| Period | Strong Buy | Buy | Hold | Sell | Strong Sell | Buy % | Distribution |
|---|---|---|---|---|---|---|---|
| Jun 1, 2026 | 5 | 6 | 1 | 0 | 0 | 92% | |
| May 1, 2026 | 5 | 6 | 1 | 0 | 0 | 92% | |
| Apr 1, 2026 | 4 | 6 | 1 | 0 | 0 | 91% | |
| Mar 1, 2026 | 4 | 5 | 1 | 0 | 0 | 90% |
Strong BuyBuyHoldSellStrong Sell
No congressional trading data available for this ticker. Data is sourced from Senate and House financial disclosure filings.
No Reddit sentiment data available yet. Sentiment is analyzed from Reddit investment communities on a rolling basis.
May 27, 2026
other
Aktis Oncology to Present at the Jefferies Global Healthcare Conference
<p>BOSTON, May 27, 2026 (GLOBE NEWSWIRE) -- Aktis Oncology, Inc. (NASDAQ:AKTS) (the “Company”), a clinical-stage oncology company focused on expandi
May 21, 2026
fda
Aktis Oncology Reports First-in-Human Clinical Imaging and Dosimetry Data for AKY-2519 Demonstrating Robust Tumor Uptake and Limited Normal Tissue Exposures in Patients with B7-H3 Expressing Tumors
<p><strong>BOSTON, May 21, 2026 (GLOBE NEWSWIRE) -- </strong>Aktis Oncology, Inc. (NASDAQ:AKTS) (Aktis or the Company), a clinical-stage oncology co
May 11, 2026
earnings
Aktis Oncology Reports Financial Results and Business Highlights for First Quarter 2026
<p>BOSTON, May 11, 2026 (GLOBE NEWSWIRE) -- Aktis Oncology, Inc. (NASDAQ:AKTS) (Aktis or the Company), a clinical-stage oncology company focused on
May 6, 2026
other
Aktis Oncology to Present at the BofA Securities Health Care Conference
<p>BOSTON, May 06, 2026 (GLOBE NEWSWIRE) -- Aktis Oncology, Inc. (NASDAQ:AKTS) (the “Company”), a clinical-stage oncology company focused on expandi
May 4, 2026
other
Aktis Oncology Initiates Phase 1b Clinical Trial for AKY-2519, a B7-H3 Miniprotein Radioconjugate, in Metastatic Castration-Resistant Prostate Cancer (mCRPC)
<p>BOSTON, May 04, 2026 (GLOBE NEWSWIRE) -- Aktis Oncology, Inc. (NASDAQ:AKTS) (Aktis or the Company), a clinical-stage oncology company focused on
Apr 21, 2026
fda
Aktis Oncology Announces Presentation of First Clinical Imaging and Dosimetry Data for AKY-2519 at the 2026 American Society of Clinical Oncology (ASCO) Annual Meeting
<p>BOSTON, April 21, 2026 (GLOBE NEWSWIRE) -- Aktis Oncology, Inc. (NASDAQ:AKTS) (the “Company”), a clinical-stage oncology company focused on expan
Apr 16, 2026
other
Aktis Oncology Appoints Industry Research and Development Veteran Glenn Gormley, MD, PhD to its Board of Directors
<p align="left">BOSTON, April 16, 2026 (GLOBE NEWSWIRE) -- Aktis Oncology, Inc. (NASDAQ:AKTS) (the “Company”), a clinical-stage oncology company foc
Mar 30, 2026
earnings
Aktis Oncology Announces FDA Clearance of Investigational New Drug Applications for AKY-2519 and Provides Business Updates and Full Year 2025 Financial Results
<p>BOSTON, March 30, 2026 (GLOBE NEWSWIRE) -- Aktis Oncology, Inc. (NASDAQ:AKTS) (the “Company”), a clinical-stage oncology company focused on expan
Mar 25, 2026
short_interest
FTD: AKTS — 52,735 shares ($1.0M) failed to deliver
Settlement: 20260325, Price: $18.63, FTD Value: $982,453.05, AKTIS ONCOLOGY INC COM
Mar 24, 2026
short_interest
FTD: AKTS — 76,605 shares ($1.4M) failed to deliver
Settlement: 20260324, Price: $18.18, FTD Value: $1,392,678.9, AKTIS ONCOLOGY INC COM
Mar 23, 2026
short_interest
FTD: AKTS — 195,591 shares ($3.5M) failed to deliver
Settlement: 20260323, Price: $17.70, FTD Value: $3,461,960.7, AKTIS ONCOLOGY INC COM